Menu
Search
|

Menu

Close
X

Oramed Pharmaceuticals Inc ORMP.OQ (NASDAQ Stock Exchange Capital Market)

3.22 USD
-0.02 (-0.62%)
As of Mar 22
chart
Previous Close 3.24
Open 3.25
Volume 532
3m Avg Volume 10,630
Today’s High 3.25
Today’s Low 3.19
52 Week High 8.50
52 Week Low 2.79
Shares Outstanding (mil) 17.38
Market Capitalization (mil) 55.96
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY19
1
FY18
2
FY17
2
FY16
1
EPS (USD)
FY19
-0.247
FY18
-0.859
FY17
-0.787
FY16
-0.864
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
58.10
Price to Sales (TTM)
vs sector
22.28
8.84
Price to Book (MRQ)
vs sector
1.94
4.60
Price to Cash Flow (TTM)
vs sector
--
40.07
Total Debt to Equity (MRQ)
vs sector
0.00
17.66
LT Debt to Equity (MRQ)
vs sector
0.00
13.97
Return on Investment (TTM)
vs sector
-38.23
12.12
Return on Equity (TTM)
vs sector
-56.19
13.24

EXECUTIVE LEADERSHIP

Kevin Rakin
Chairman of the Board, Independent Director, Since 2016
Salary: --
Bonus: --
Nadav Kidron
President, Chief Executive Officer, Director, Since 2006
Salary: $273,086.00
Bonus: $195,729.00
Hilla Eisenberg
Chief Financial Officer, Treasurer, Secretary, Since 2017
Salary: --
Bonus: --
Miriam Kidron
Chief Scientific Officer, Director, Since 2006
Salary: $203,378.00
Bonus: $136,583.00
Mark Hasleton
Vice President - Business Development, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

142 W 57th St Fl 11
NEW YORK   NY   10019-3590

Phone: +9722.5660001
Site: oramed.com

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

SPONSORED STORIES